Welcome to our dedicated page for Cargo Therapeutics SEC filings (Ticker: CRGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical data tables, option-grant footnotes and sudden 8-K trial updates make <>Cargo Therapeutics (CRGX)<> filings some of the toughest reads in biotech. Finding the CD22 response rates or spotting a shelf registration that hints at future dilution can mean parsing hundreds of pages. Our platform delivers Cargo Therapeutics SEC filings explained simply, turning dense disclosures into clear, AI-generated summaries you can trust.
Every document posted to EDGAR is captured in real time and decoded by Stock Titan’s AI so you see what matters first. Need the Cargo Therapeutics quarterly earnings report 10-Q filing even though revenue is still years away? We tag the R&D burn rate, cash runway and milestone payments automatically. Curious about Cargo Therapeutics insider trading Form 4 transactions? Receive instant alerts on Cargo Therapeutics Form 4 insider transactions real-time and track each executive stock move. Our coverage spans:
- 10-K � Cargo Therapeutics annual report 10-K simplified with cash-runway and risk-factor highlights.
- 10-Q � Quarter-over-quarter trial spend and liquidity trends.
- 8-K � Cargo Therapeutics 8-K material events explained, from FDA meetings to manufacturing outages.
- Form 4 � Cargo Therapeutics executive stock transactions Form 4 distilled into buy/sell dashboards.
- DEF 14A � Cargo Therapeutics proxy statement executive compensation parsed for option grants and milestones.
Whether you’re monitoring trial milestones, calculating dilution risk, or seeking a quick Cargo Therapeutics earnings report filing analysis, our AI-powered summaries, side-by-side comparisons and keyword search help you cut research time from hours to minutes. Start understanding Cargo Therapeutics SEC documents with AI today and make better decisions with complete, timely information.
CARGO Therapeutics, Inc. (Nasdaq: CRGX) has entered into a definitive Agreement and Plan of Merger with Concentra Biosciences, LLC and its wholly-owned subsidiary Concentra Merger Sub VII, Inc. (together, “Concentra�). The transaction will be executed through a two-step structure consisting of (1) a cash tender offer followed by (2) a Section 251(h) short-form merger.
Key economic terms
- Offer price: $4.379 in cash per CRGX share (the “Cash Amount�) plus one non-transferable contingent value right (CVR).
- CVR mechanics: � 100 % of Closing Net Cash in excess of $217.5 million; � 80 % of net proceeds from any sale/license/other disposition of CRG-022, CRG-023 or the Company’s allogeneic platform completed within two years post-closing. If no disposition occurs within that window, no CVR payment is due.
- Minimum tender condition: more than 50 % of the voting common stock (excluding guaranteed delivery) must be validly tendered and not withdrawn.
- Net-cash condition: Company’s Closing Net Cash must be � $217.5 million at closing.
- No financing condition: Concentra must close irrespective of market financing availability.
- Termination fees: � $3.8 million payable by CARGO upon certain superior proposal scenarios; � up to $0.5 million expense reimbursement to Concentra if Closing Net Cash falls below the threshold.
- Support agreements: Directors, officers and certain shareholders holding ~17.4 % of outstanding shares have contractually agreed to tender.
The Board of Directors of CARGO unanimously determined the offer and merger to be fair and in the best interests of shareholders, approved the Merger Agreement and recommended shareholders tender their shares. Concentra must commence the tender offer within ten business days of 7 July 2025; the merger will follow promptly after successful completion of the offer, without a further shareholder vote.
Limited guaranty: Tang Capital Partners, LP has issued a guaranty capped at $213.1 million (plus defined CVR amounts) covering certain Concentra/Merger Sub obligations.
Regulation FD disclosure: A press release announcing the transaction was issued 8 July 2025 (Ex. 99.1). Investors are urged to read the forthcoming Schedule TO and Schedule 14D-9 for complete terms.
Implications for investors
- Provides near-term liquidity via cash consideration while retaining upside through the CVR structure.
- No shareholder vote required post-tender, accelerating closing timeline (outside date 4 Nov 2025).
- Completion risk centers on achieving the 50 % tender minimum, maintaining � $217.5 million net cash, and regulatory clearances (no financing contingency exists).
- CVR value is uncertain and contingent on (i) actual closing net-cash and (ii) ability to monetise pipeline assets within two years.
CARGO Therapeutics (CRGX) � Form 4 filing dated 07/03/2025 details a small insider transaction by Interim CEO/CFO/COO Anup Radhakrishnan.
- Transaction: Sale of 1,632 common shares on 07/02/2025 at an average price of $4.18 per share.
- Purpose: The sale was executed solely to satisfy tax-withholding obligations arising from the vesting of restricted stock units (RSUs).
- Post-sale ownership: Radhakrishnan continues to hold 120,781 common shares directly.
- Role: Insider currently serves as Interim Chief Executive Officer, Chief Financial Officer and Chief Operating Officer.
The transaction represents roughly 1.3% of the insider’s reported direct holdings and does not reflect a discretionary reduction in economic exposure. No derivative activity or additional equity awards were reported.
Transportadora de Gas del Sur S.A. (TGS) has filed a Form 6-K to announce that the Argentine gas regulator ENARGAS issued Resolution 421/2025, published in the Official Gazette on 1 July 2025, approving new tariff charts for the company.
- Automatic monthly adjustment: Tariffs will now be updated every month using the formula set out in Energy Bureau Resolution 241/2025 and approved by ENARGAS Resolution 350/2025. The formula gives a 50 % weight to the national Consumer Price Index (IPC) and 50 % to the Wholesale Price Index (IPIM). The first application produces a 0.62 % tariff increase.
- Five-year review increase: An additional rise for transportation services is introduced pursuant to Section 5 of ENARGAS Resolution 256/2025. The filing does not state the percentage size of this component.
The company states that these adjustments apply to its regulated gas transportation business and were communicated as a material fact to the Argentine capital markets. No further financial, operational or guidance information was included.
SEC Form 4 Filing Overview � Cargo Therapeutics, Inc. (CRGX)
On 20 June 2025, Cargo Therapeutics filed a Form 4 disclosing a routine equity award to board member Krishnan Viswanadhan. On 18 June 2025, the director received a stock-option grant for 25,000 common shares with an exercise price of $4.35 per share and an expiration date of 17 June 2035. The filing records the transaction with code “A,� indicating an award rather than an open-market purchase or sale.
Vesting terms: 100 % of the option vests on the earlier of (i) the one-year anniversary of 18 June 2025 or (ii) the next annual shareholder meeting, provided the director continues to serve. No shares were sold and no cash price was paid at grant (price of derivative security reported as $0), so the transaction is non-cash and non-dilutive at grant, affecting dilution only if the exercise price is paid and shares are issued in the future.
Ownership impact: Following the grant, Viswanadhan beneficially owns 25,000 derivative securities (options) and no change was reported for non-derivative common stock holdings. The filing does not reference any 10b5-1 trading plan, dispositions, or changes in board composition.
Materiality assessment: Director option grants of this size are typical for early-stage biotech boards and do not materially alter the company’s capital structure or near-term cash flow. Consequently, the disclosure is viewed as routine corporate governance information with limited immediate market impact.
CARGO Therapeutics, Inc. (CRGX) Form 4 filing: Director Reid M. Huber disclosed the grant of 25,000 stock options on 18 Jun 2025 with a $4.35 exercise price. The award conveys the right to acquire an equal number of common shares and will vest 100 % on the earlier of (i) 18 Jun 2026 or (ii) the company’s next annual meeting, provided continued board service. The options carry a ten-year term, expiring 17 Jun 2035, and were issued at no upfront cost. Post-grant, Huber beneficially owns 25,000 derivative securities, with no common stock purchased or sold. The filing, signed 20 Jun 2025, reflects routine director compensation and has negligible immediate dilution or cash-flow impact.
CARGO Therapeutics, Inc. (CRGX) � Form 4 filing
The filing discloses that director Abraham Bassan received a stock-option grant for 25,000 shares of CRGX common stock on 18 June 2025. The option carries an exercise price of $4.35 and will expire on 17 June 2035.
Vesting is 100% on the earlier of (i) the one-year anniversary of the grant date or (ii) the next annual shareholders� meeting, contingent upon continued service. No shares were sold or otherwise disposed of; Bassan’s beneficial ownership now includes the 25,000 unexercised options, recorded as directly held.
The transaction appears to be a routine equity incentive designed to align director interests with those of shareholders. There are no accompanying cash transactions, sales, or changes in ownership structure noted in this filing.
CARGO Therapeutics, Inc. (CRGX) � Form 4 insider filing dated 06/20/2025
The filing discloses a single equity-based transaction involving Director Kapil Dhingra. On 06/18/2025, Dr. Dhingra was granted a stock option for 25,000 common shares with an exercise price of $4.35 per share. The option vests 100 % on the earlier of (i) the one-year anniversary of the grant date or (ii) the next annual shareholder meeting, provided the director continues to serve the company. The option expires on 06/17/2035. After this grant, Dr. Dhingra now holds 25,000 derivative securities (options) directly.
No non-derivative share transactions were reported, and there were no sales or exercises associated with the option. The transaction was reported on a Form 4 filed by one reporting person; no 10b5-1 trading plan box was checked. The filing represents routine director compensation rather than an open-market purchase or sale.
For investors, the disclosure indicates additional potential dilution of up to 25,000 shares (�0.1 % of a typical small-cap biotech float) should the option be exercised, while also aligning the director’s incentives with long-term shareholder value via equity compensation.
CARGO Therapeutics, Inc. (CRGX) � Form 4 filing dated 20 June 2025
The filing discloses that non-employee director David Charles Lubner received a routine equity incentive on 18 June 2025: a stock option for 25,000 shares of common stock with an exercise price of $4.35 and an expiration date of 17 June 2035. All 25,000 options will vest 100 % on the earlier of (i) the one-year anniversary of the grant date or (ii) the company’s next annual meeting, conditional upon the director’s continued service. Following this grant, Mr. Lubner beneficially owns 25,000 derivative securities, held directly. No open-market purchases, sales, or changes to non-derivative share ownership were reported.
Because the filing represents a standard board option grant, it does not alter the company’s capital structure or signal insider buying or selling of common shares. The information is therefore operationally routine and financially immaterial for most investors, though it demonstrates continued alignment of director incentives with shareholder value.
CARGO Therapeutics, Inc. (CRGX) filed a Form 4 disclosing a routine equity award to director Jane Henderson.
On 18 June 2025, Henderson received a stock option covering 25,000 common shares with an exercise price of $4.35. The option vests 100 % on the earlier of (i) 18 June 2026 or (ii) the company’s next Annual Meeting, contingent on her continued board service. The instrument carries a 10-year term, expiring 17 June 2035. Following the grant, Henderson’s beneficial ownership of derivative securities totals 25,000 options; no non-derivative share transactions were reported.
The filing is noted as a single-person submission, confirms Henderson’s status solely as a director, and contains no indication of a Rule 10b5-1 trading plan. No sales, purchases, or other equity movements were disclosed beyond this compensatory award.
On 20 June 2025, Udemy, Inc. (UDMY) filed a Form 4 reporting that independent director Sohaib Abbasi was granted 27,476 restricted stock units (RSUs) on 17 June 2025 under the company’s outside-director compensation policy. The grant is coded “A� (acquisition) at a price of $0, indicating a share-based award rather than an open-market purchase. Abbasi’s direct beneficial ownership increases to 97,365 common shares following the transaction.
The RSUs vest in full on the earlier of (i) Udemy’s next annual shareholder meeting or (ii) one year from the grant date, provided Abbasi continues to serve as a director. He has additionally elected to defer settlement until the earlier of 1 January 2029 or his separation from the board, signalling a long-term alignment with shareholder interests. The award represents less than 0.02 % of shares outstanding and is therefore immaterial from a dilution perspective. Overall, this is a routine insider compensation disclosure with no expected impact on Udemy’s fundamental outlook.
FAQ
What is the current stock price of Cargo Therapeutics (CRGX)?
What is the market cap of Cargo Therapeutics (CRGX)?
What does Cargo Therapeutics specialize in?
What is CRG-022 (firi-cel)?
How does Cargo Therapeutics differentiate itself from competitors?
What challenges does Cargo Therapeutics address in CAR T-cell therapy?
What is the significance of Cargo's tri-cistronic CAR T technology?
What types of cancers does Cargo Therapeutics target?
What is Cargo Therapeutics' approach to manufacturing?
Who are Cargo Therapeutics' competitors?
What is the broader impact of Cargo Therapeutics' work?
